Envoy Medical Files 8-K: Material Agreement & Financials
Ticker: COCHW · Form: 8-K · Filed: Dec 17, 2024 · CIK: 1840877
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation, equity-securities
TL;DR
Envoy Medical signed a big deal, took on debt, and sold stock. Big changes coming.
AI Summary
Envoy Medical, Inc. entered into a material definitive agreement on December 11, 2024, which also created a direct financial obligation for the registrant. The filing also disclosed unregistered sales of equity securities and included financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant financial and contractual developments for Envoy Medical, Inc., potentially impacting its financial obligations and equity structure.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements and financial obligations, which can introduce financial risks and changes in equity structure.
Key Players & Entities
- Envoy Medical, Inc. (company) — Registrant
- December 11, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did Envoy Medical, Inc. enter into?
The filing states that Envoy Medical, Inc. entered into a material definitive agreement on December 11, 2024, but does not specify the exact nature of the agreement in the provided text.
What is the nature of the direct financial obligation created for Envoy Medical, Inc.?
The filing indicates the creation of a direct financial obligation for Envoy Medical, Inc. as of December 11, 2024, but the specific details of this obligation are not provided in the text.
Were there any unregistered sales of equity securities by Envoy Medical, Inc.?
Yes, the filing explicitly mentions 'Unregistered Sales of Equity Securities' as an item of information reported by Envoy Medical, Inc.
What is the fiscal year end for Envoy Medical, Inc.?
The fiscal year end for Envoy Medical, Inc. is December 31.
What is the SEC file number for Envoy Medical, Inc.'s 8-K filing?
The SEC file number for this 8-K filing is 001-40133.
Filing Stats: 668 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-12-17 16:00:14
Key Financial Figures
- $0.0001 — tered Class A Common Stock, par value $0.0001 per share COCH The Nasdaq Stock Mar
- $11.50 — A Common Stock at an exercise price of $11.50 per share COCHW The Nasdaq Stock Ma
- $5,000,000 — nvoy Medical, Inc. (the "Company") drew $5,000,000 under the promissory note (the "Note")
- $10,000,000 — Note to the maximum principal amount of $10,000,000. As a commitment fee for the $5,000,0
- $2 — ). The Warrant has an exercise price of $2.20, equal to the closing price on the d
Filing Documents
- ea0225002-8k_envoy.htm (8-K) — 38KB
- 0001213900-24-109750.txt ( ) — 251KB
- coch-20241211.xsd (EX-101.SCH) — 4KB
- coch-20241211_def.xml (EX-101.DEF) — 26KB
- coch-20241211_lab.xml (EX-101.LAB) — 36KB
- coch-20241211_pre.xml (EX-101.PRE) — 25KB
- ea0225002-8k_envoy_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENVOY MEDICAL, INC. December 17, 2024 By: /s/ David R. Wells David R. Wells Chief Financial Officer 2